Life
Science

Physics & Engineering

Your search found 11 results

Chemerin9 Variants for Diagnosis and Therapy of Pancreatic and Oesophageal Cancer

07.03.2012 | Ref.Nr. 11115

Life Science › Medical Devices › Imaging

Imaging of subcutaneous oesophageal tumors at the flanks of the animals with labeled vChem9 peptide (source: Grötzinger, Bandholz, NP2D 2011).Background
Pancreatic and oesophageal tumors are comparatively rare but characterized by high mortality rates. One reason is that such tumors are commonly detected only at advanced stages of cancerous disease. Often the disease is detected by chance, for instance during the course of other medical examinations.

Technology
Occurrence of CMKLR1, a G protein-coupled receptor, was found to be elevated in oesophageal squamous cell carcinoma and pancreatic adenocarcinoma. We offer peptidic variants of CMKLR1 ligand Chemerin9 with highest stability and optimized ligand binding properties. Attached to a detectable label or therapeutically active agent the peptide variants are suitable for imaging of mestastases formation in pancreatic and oesophageal tumors and its therapy in a theranostic approach.

IP Rights
European priority application filed

Patent Owner
Charité – Universitätsmedizin Berlin

Application Area:

Predictive imaging, Therapy monitoring, Micro-dosing approach

Development Stage: in vivo

Tags: Imaging, micro dosing delivery, theranostics, tumor therapy,

Further Categories: Diagnostics, Life Science, Medical Devices, Imaging

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Suitable Industry: Diagnostics, Biotechnology, Pharmaceuticals

Benefits:

Reliable diagnosis of primary pancreatic and oesophageal tumors
Promising Target: CMKLR1
Reliable detection of early metastases
Suitable for routine medical screening

Bisphosphonates as Potential Drug Candidates for Inflammatory Lung Diseases

15.02.2012 | Ref.Nr. 09061

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Biphosphonate with a prolonged carbon chain.Background
Recent findings in animal models underline the potential role of the acid sphingomyelinase (aSMase) as an important drug target in inflammatory lung diseases like acute lung injury (ALI) - the main cause of death in intensive care units -, acute respiratory distress syndrome (ARDS), lung emphysema, and cystic fibrosis.

The invention offers simple geminal bisphosphonates with a prolonged carbon chain as potent and selective inhibitors of the acid sphingomyelinase. The compounds can be synthesized in a one-step or two-step procedure and show clear inhibition of cell death in vitro. First ex vivo data in rats show a reduction of platelet activating factor (PAF) – induced pulmonary edema in the presence of the bisphosphonates by at least 50 percent. Aerosols of bisphosphonates may be possible applicants for the treatment of pulmonary diseases.

Besides their use in inflammatory lung diseases the bisphosphonates with prolonged carbon chain may be used as a treatment option for cystic fibrosis and atherosclerosis.

IP Rights
EP Application (08/2009).
PCT Application (08/2010).
A PCT application was filed in August 2010.

Patent Owner
Humboldt-Universität zu Berlin
Rheinisch-Westfälische
Technische Hochschule Aachen (RWTH)

Application Area:

Drug candidates for the treatment of inflammatory lung diseases, cystic fibrosis and atherosclerosis.

Development Stage: Ex vivo

Tags: Acid Sphingomyelinase, athero-sclerosis, bisphosphonate, cystic fibrosis, inflammatory lung diseases, Inhibitor,

Further Categories: Life Science, Medical Devices, Pharma & Biotech

Licensing Manager: Dr. Bettina Büttner

T +49 30 2125 4835

F +49 30 2125 4822

bettina.buettner@ipal.de

Suitable Industry: Pharmaceuticals

Benefits:

Neutral sphingomyelinase is not influenced
First ex-vivo data in a PAF-induced edema rat model showed clear edema reduction by 50percent
Inhibition of dexamethasone induced apoptosis was proven in vitro
Substances can easily be synthesized in a one-step or two-step procedure
Prolongation from 6 to 8 C-atoms shows 40times higher inhibition rate

New Pill Package - Applicator for Ointments

12.05.2011 | Ref.Nr. 10049

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

The invention offers two new packaging methods for pills and ointments. Advantage of the packagings is the one-hand operation and the sterile application of the drug.

Pills are fixed on a carrier item that is airtight sealed in a blister-like packaging. It enables the patient to take the pill sterile with one hand from the carrier item. Particularly, the pill goes straight to the mouth of the patient and any contact with the possibly unwashed hands or the non-sterile environment is avoided.

The invented pill dispenser can have marks for the weekdays and daytimes. Additionally it has a fixed patient information leatflet, so that a mixing up with other drugs becomes excluded.

For the sterile application of an ointment a small map packaging was invented. Therefore, the ointment is airtight sealed on a cushion at the end of a rodlike carrier item. The rodlike carrier items are alternating fixed on the map packaging and one map contains as many dosages as needed for one day.

The patient is able to apply target-oriented a defined dosage of one use sterile at every time and everywhere. Therefore, the packaging is special on the way extremely convenient.

IP Rights
German Patent Application, filed on August 6, 2010

Origin
Hochschule für Technik und Wirtschaft Berlin, Germany

Application Area:

Drug packaging

Development Stage: Prototyp

Type of Collaboration: License

Tags: blister, dosage, one-hand, package, pill, sterile,

Further Categories: Life Science, Medical Devices, Pharma & Biotech

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Market Potential: Worldwide

Benefits:

Sterile application of drugs
One-hand operation
Simply application being on the way

CEACAM8: Promising Therapeutic Agent with Pleiotropic Effects

09.07.2010 | Ref.Nr. 05100

Download as PDF PDF Download Share

Life Science › Pharma&Biotech

Granulocytes form the first and fastest line of defense against pathogenic infections. They participate in the inflammatory reaction by phagocytosis, release of cytotoxic compounds and pro-inflammatory cytokines and generation of ROS.

Most recently it was shown that membrane-anchored CEACAM8 triggers apoptosis in granulocytes. Thus, substances binding specific to membrane-bound CEACAM8 are useful to treat human autoimmune diseases or gout.

We offer soluble CEACAM6 or CEACAM8 proteins to manufacture a medicament for prophylactic or therapeutic treatment of human autoimmune diseases, gout, cancer or infection diseases.

Moreover, we offer antibodies directed against CEACAM8 or CEACAM6 that inactivate the functions triggered by soluble CEACAM6 and CEACAM8, respectively. Thus, the specific antibodies can be utilized as therapeutcis to prevent the pleiotropic effects induced by physiological released CEACAMs.

IP Rights
European patent applications filed in November 2005 and September 2007. US patent application filed in October 2006.

Origin
The technology was developed at the Charité (Berlin/Germany).

Application Area:

Pharma, Medicine

Development Stage: Lab scale

Type of Collaboration: License

Tags: Apoptosis, Autoimmune, CEACAM8, Granulocytes, Infections, Inflammatory, Membrane, Therapeutic, Toxic,

Further Categories: Life Science, Immunology & Infection, Medical Devices, Pharma & Biotech

Licensing Manager: Marcel Tilmann

T +49 30 2125 4827

F +49 30 2125 4822

marcel.tilmann@ipal.de

Market Potential: Worldwide

Benefits:

CEACAM8 is a human molecule that can be produced in high purity
Recombinant (soluble) CEACAM8 regulates various functions of CEACAM1 expressing cells
CEACAM8 binds the adhesion receptor of CEACAM1 that is expressed on leucocytes, epithelial cells and activated endothelial cells
CEACAM8 is non-homophilic and thus does not inactivate itself during storage
CEACAM8 does not bind pathogens, as other CEACAMs do à pathogens cannot inactivate CEACAM8
Principle can be used as therapeutic approach in various indications

Body-Surface-Potential-Maps by utilizing a standard ECG device

19.03.2010 | Ref.Nr. 03017

Download as PDF PDF Download Share

Life Science › Medical Devices

Receiving a standard 12-lead electro-cardiogram (ECG) is a well established method to get information of the heart's electrical activity recorded from electrodes on the body surface. In comparison to standard ECG, Body-Surface-Potential-Mapping (BSPM) is an advanced method providing more extensive and precise diagnostic data.

The reason for an improved detection and separation of pathophysiological heart function by BSPM is due to the much larger number of sampling positions of the electrodes attached to the thorax. Hence, spatially and temporally important features may be captured by BSPM but not by the 12-lead-ECG. So far, high cost and complexity have presented widespread use of BSPM in clinical settings.

Our new method requires only a standard 12-lead ECG device with digital data output providing almost identical results as BSPM. The only real difference is that not all channels are being read out simultaneously, i.e. the mapping is reconstructed from sequentially obtained ECG-Signals. A specific digital signal processing has been developed to synchronize sequentially recorded ECG signals. The resulting data is thus competitive to the “true” parallel BSPM.

IP Rights
German Patent DE 10 336 809 B4; European Patent Application EP 1653851 A1

Origin
Charité, Campus Benjamin Franklin, Berlin, Germany; Physikalisch-Technische Bundesanstalt (PTB), Berlin, Germany

Application Area:

Medical Technology

Development Stage: Lab level

Type of Collaboration: License, Sale, Cooperation

Tags: 12-lead ECG, Body, BSPM, Cardio, Diagnostic, Digital Signal, ECG, Heart,

Further Categories: Life Science, Medical Devices

Licensing Manager: Dr. Kirk Haselton

T +49 30 2125 4842

F +49 30 2125 4822

kirk.haselton@ipal.de

Market Potential: Worldwide

Benefits:

Additional benefit for users of 12-lead-EVG devices
Simple and cost-effective method to get additional clinically relevant data
The algorithms may easily be added to the software of commercial digital ECG devices

Intravenous Catheter: A New IV Catheter Device Featuring Automatic and Integrated Blood Sampling

05.01.2010 | Ref.Nr. 04091

Download as PDF PDF Download Share

Life Science › Medical Devices › Regenerative medicine

We offer a new IV catheter for the use during emergency and disasters to automatically preserve a pre-infusion bloodsample from every patient. The new catheter system is based on existing IV devices. Its new features include an integrated blood sampling reservoir that is fixed to the IV catheter via a flexible plastic band and remains attached to the patient following self-filling with a small blood volume until admission in the hospital. Upon arrival, the reservoir is labeled with the patient ID, disconnected from the patient and immediately sent to the laboratory for blood group typing.

Thus, the device ensures rapid and precise ABO typing in 100% of emergency patients. Furthermore, it increases patient safety by securing this precious very first blood sample in every case in addition to the sample taken from a central line inserted inside the hospital. Thereby two independently drawn specimens are available for ABO-typing even in circumstances with extreme time constraints.

IP Rights
Patent pending in the US, EP, and DE

Origin
The catheter system was developed at the Charité – Universitätsmedizin Berlin.

Application Area:

Emergency Medicine, Medical Technology, Military

Development Stage: Clinical tests

Type of Collaboration: License

Tags: Blood, Catheter, Laboratory, Patient, Sampling,

Further Categories: Life Science, Medical Devices, Regenerative medicine

Licensing Manager: Marcel Tilmann

T +49 30 2125 4827

F +49 30 2125 4822

marcel.tilmann@ipal.de

Market Potential: Worldwide

Benefits:

Secure blood transfusions
Increased patient security
Catheter and reservoir are both labeled with the patient ID to avoid false blood infusions
Rapid and precise ABO typing

New Methods for Elastography of the Liver, Heart and Brain

20.10.2009 | Ref.Nr. 06023

Download as PDF PDF Download Share

Life Science › Medical Devices › Imaging

The new methods are based on magnetic resonance imaging (MRI), magnetic resonance elastography (MRE), and ultrasonography (US). The main goal of the inventions is to diagnose cardiac dysfunction by non-invasive elasticity measurements using either MRI or US. Additionally, the innovative methods considerably improve MRE of liver fibrosis and potentially allow an elasticity-based diagnosis of neurodegenerative diseases.

The new methods are based on three crucial developments:

Rigid transmission of shear waves into the body. This allows robust mechanical stimulation of liver, heart and brain by arbitrary waveforms using relatively high wave amplitudes without destructive interferences and discomfort to the patient. (MRI and US)
Accelerated magnetic encoding of slow tissue vibrations (fractional MRE). This for the first time allows the acquisition of externally induced oscillations by MRI during cardiac motion. (MRI)
Assessment of cardiac function using modulated shear waves. This is a simple and unique way to measure intraventricular pressure changes without the need for invasive catheter examinations. (MRI and US)

IP Rights
06023    EP Application, Publ. No. EP2007281 (A1).
06023    DE Application, Publ. No. DE102006037160 (A1).
06024    DE Application, Publ. No. DE102006062763 (A1).
06023    US Application No. 12/297,133.
07023    German Patent Application DE 102007022469 filed on May 8, 2007.
07023    PCT Application PCT/EP 2008/055617 filed on May 7, 2008.

Origin
Charité Berlin

Application Area:

Medical

Development Stage: Concept

Type of Collaboration: License, Sale, Collaboration

Tags: Body, Cardiac Dysfunction, Diagnose, Magnetic Resonance Elastography, Magnetic Resonance Imaging, MRE, MRI, Ultrasonography, US,

Further Categories: Life Science, Medical Devices, Imaging

Licensing Manager: Dr. Kirk Haselton

T +49 30 2125 4842

F +49 30 2125 4822

kirk.haselton@ipal.de

Market Potential: Worldwide

Benefits:

The techniques can be combined for the diagnosis of heart failure or to acquire ventricular pressure data without catheter intervention. In other applications rigid wave transmission can be combined with fractional MRE to improve the accuracy and significance of liver MRE, thereby avoiding harmful and expensive biopsies.

A bone cement composition for the creation of a MRT-signaling bone cement

14.09.2009 | Ref.Nr. 07147

Download as PDF PDF Download Share

Life Science › Medical Devices › Regenerative medicine

Bone cements based on polymethylmethacrylate (PMMA) are mostly used for the anchorage of artificial joints, as bone substitutes at backbone diseases or after tumour surgeries, for the encouragement of implants (e.g. plates, nails) or as placeholder in infected joints. Most bone cements are produced by the combination of a 2-phase-system, containing a powder (PMMA) and a fluid (MMA).

Especially during the insertion of bone cement into fractured vertebral bodies or cleared tumour caves (vertebroplasty) it is necessary to follow the operation process by MR imaging to ensure the right position of the bone cement (“open MRI”). Therefore the researchers developed bone cement with paramagnetic properties to induce a MRT detectable signal. They added sodium chloride solution containing a contrast agent to the MMA and proceeded as done by common bone cement production. In this way they achieved modified bone cement that can induce a MR signal by keeping all conventional properties.

IP Rights
A PCT application was filed on February 2nd, 2009 (priority on February 2nd, 2008)

Origin
The technology was developed at Charité - Universitätsmedizin Berlin.

Application Area:

Pharma & Medical

Development Stage: Proof of Concept

Type of Collaboration: License

Tags: Bone Cement, MRT, PMMA,

Further Categories: Life Science, Medical Devices, Regenerative medicine

Licensing Manager: Dr. Janin Hofmann

T +49 30 2125 4828

F +49 30 2125 4822

janin.hofmann@ipal.de

Market Potential: Worldwide

Benefits:

Low technical risk
Growing market for implants
MRT-controlled surgeries are possible
Overcomes the disadvantage of common bone cement not to generate a signal detectable by MR imaging

Fast prognostic test kit for bone regeneration after fracture

10.03.2009 | Ref.Nr. 08132

Download as PDF PDF Download Share

Life Science › Medical Devices

A fast prognostic test helps to avoid a painful and expensive treatment of patients with complications in bone healing after fracture. Every second woman and eighth man over age of 50 suffers from bone fracture or defect. 20% of the patients face a serious delay in healing or even complications after the surgery. In most cases the reason for complications is a low level of endogenous growth factors necessary to induce the healing process. In case of complications the wound has to be opened again to apply the treatment.

To avoid the painful and expensive re-opening of the wound and a delayed treatment after bone fracture a new test kit was developed to facilitate the prognosis of possible healing problems in a patient. The prognostic test can easily be performed in a time frame of max. 60 minutes during the first surgery. The new test kit allows the sampling direct from the fracture environment and application on the array containing the diagnostic parameters. The test relates to the amount of growth factors present shortly after bone fracture and allows a prognosis for a disposition for complications in a patient. The prognostic test is constructed as a point-of care tool that is easy to handle, robust and cheap but delivers reliable results.

IP Rights
US Provisional with priority on 01/10/2008

Origin
The development was made by the German institutions Charité – Universitätsmedizin Berlin.

Application Area:

Medical Technology, Transplantation

Development Stage: In vitro

Type of Collaboration: License

Tags: Healing, Intra-Operative, Prognosis of Bone Healing,

Further Categories: Life Science, Single use devices & implants, Medical Devices

Licensing Manager: Marcel Tilmann

T +49 30 2125 4827

F +49 30 2125 4822

marcel.tilmann@ipal.de

Market Potential: Worldwide

Benefits:

Point-of-care test kit
Test allows prognosis on healing process in the emergency case (first surgery)
Fast, robust and cheap test kit
Easy to handle, sampling and prognostic test is combined in one tool, no transfer needed of the sample to an array

Combined Application of an Agent Carrying a Target-Cell Specific Ligand and a Saponin

16.02.2009 | Ref.Nr. 04047

Download as PDF PDF Download Share

Life Science › Medical Devices › Regenerative medicine

We offer a novel approach for a high uptake of a pharmacologically active agent and an enhanced specificity towards its target. One of the most significant problems in tumor therapy is the incomplete removal of tumors by local treatment, since a complete and lasting tumor remission by chemotherapy or radiation therapy works only for a few tumor entities.

Therefore, a promising approach to solve this problem is an immunological therapy by which a pharmacologically active agent is applied to a patient with preferable high tumorspecificity. However, quite frequently, one is not able to achieve sufficiently large concentrations of the pharmacologically active agent at the intended site of action, either because the agent never reaches the site in the first place or is metabolized too quickly without being able to exert its action. One way of approaching this problem in the past has been to combine the pharmacologically agent with a target specific component so as to increase the likelihood of the agent reaching the target.

IP Rights
EP 04 016 497.2 filed on July 13, 2004, US, JP

Origin
The technology was developed at the Charité - Universitätsmedizin Berlin/Germany.

Application Area:

Pharmaceutical industry

Development Stage: Preclinic

Type of Collaboration: License

Tags: Cellular Targeting, Pharmacological, Saponin, Tumor,

Further Categories: Life Science, Medical Devices, Regenerative medicine

Licensing Manager: Marcel Tilmann

T +49 30 2125 4827

F +49 30 2125 4822

marcel.tilmann@ipal.de

Market Potential: Worldwide

Benefits:

By combining the application of pharmacologically active agents (such as cytotoxins in the case of tumor therapy, e. g. Ontak™) carrying target-cell specific ligands with a saponin, the uptake of the agent can be enhanced more than ten thousand fold. Due to this specific enhancement, the total concentration of the agent can be reduced by a comparable factor still achieving the desired effects towards e. g. tumor cells. Severe side-effects, however, such as cytotoxicity towards benign cells, are thereby suppressed. Target cell specific ligands can be covalently coupled or non-covalently associated to the pharmacologically active agent or can be expressed as a fusion protein with the agent. Beside the application in tumor therapy, a more general approach can be anticipated regarding any therapy in which difficulties in transferring an agent into a specific
compartment exist (e. g. treatment of inflammatory diseases by cell-specific inhibition of inflammatory mediators).